Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
50g |
|
||
Other Sizes |
|
Purity: ≥98%
Lidocaine (Alphacaine; NSC-40030; NSC40030; Lignocaine), a local anesthetic and cardiac depressant used as an antiarrhythmia agent, is a potent and selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Lidocaine, a long-acting membrane stabilizing agent that prevents ventricular arrhythmia, was first created as a local anesthetic and is a member of the class IB antiarrhythmics. It works for a shorter amount of time than prilocaine or bupivacine.
Targets |
Histamine H1 receptor ( IC50 > 32 μM )
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Cell Assay |
Cell Line: The human gastric cancer cell line MKN45
Concentration: 10 nM Incubation Time: 48 hours Result: Decreased significantly cell proliferation. |
||
Animal Protocol |
|
||
References |
|
Molecular Formula |
C14H22N2O
|
|
---|---|---|
Molecular Weight |
234.34
|
|
Exact Mass |
234.17
|
|
Elemental Analysis |
C, 71.76; H, 9.46; N, 11.95; O, 6.83
|
|
CAS # |
137-58-6
|
|
Related CAS # |
Lidocaine hydrochloride; 73-78-9;Lidocaine (Standard); 137-58-6; Lidocaine hydrochloride hydrate; 6108-05-0; Lidocaine; 137-58-6; N-Oxide Lidocaine-d10; 851528-10-4; Lidocaine-d10; 851528-09-1
|
|
Appearance |
Solid powder
|
|
SMILES |
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C
|
|
InChi Key |
NNJVILVZKWQKPM-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)
|
|
Chemical Name |
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.67 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 4.35 mg/mL (18.56 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.2673 mL | 21.3365 mL | 42.6730 mL | |
5 mM | 0.8535 mL | 4.2673 mL | 8.5346 mL | |
10 mM | 0.4267 mL | 2.1337 mL | 4.2673 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04840511 | Active Recruiting |
Drug: lidocaine group Drug: control group |
Urologic Cancer | The Catholic University of Korea | September 27, 2021 | Not Applicable |
NCT03865940 | Active Recruiting |
Drug: Lidocaine Drug: Guanfacine |
Trigeminal Neuralgia | Vanderbilt University Medical Center |
November 4, 2019 | Phase 2 |
NCT02229578 | Active Recruiting |
Drug: Lidocaine Drug: Placebo |
Pain | University of Florida | September 2014 | N/A |
NCT01916317 | Active Recruiting |
Drug: 0.5% lignocaine 60mM | Operable Breast Cancer | Tata Memorial Hospital | December 12, 2011 | Phase 3 |
NCT04176419 | Active Recruiting |
Drug: Ketamine Drug: Placebo Ketamine Drug: Lidocaine Drug: Placebo Lidocaine |
Postoperative Pain Control Opioid Consumption |
Case Comprehensive Cancer Center |
January 17, 2020 | Phase 3 |
The growth of MKN45 cells was inhibited by lidocaine. BMC Cancer . 2019 Mar 15;19(1):233. td> |
The MKN45 cells migration and invasion were inhibited by lidocaine. BMC Cancer . 2019 Mar 15;19(1):233. td> |
The relative expression of miR-145 was enhanced by lidocaine treatment. BMC Cancer . 2019 Mar 15;19(1):233. td> |